Validation Data Gallery
|Positive WB detected in
|Daudi cells, Raji cells, Ramos cells
|Positive IP detected in
|Positive IHC detected in
|human lymphoma tissue, human tonsillitis tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive FC detected in
|Western Blot (WB)
|WB : 1:500-1:2000
|IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
|IHC : 1:50-1:500
|Flow Cytometry (FC)
|FC : 1:10-1:100
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
26709-1-AP targets BSAP,PAX5 in WB, IP, IHC, FC, ELISA applications and shows reactivity with human, mouse samples.
|Host / Isotype
|Rabbit / IgG
|BSAP,PAX5 fusion protein Ag25147
|paired box 5
|Calculated molecular weight
|391 aa, 42 kDa
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Antigen affinity purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
PAX5, also named B-cell specific activator protein (BSAP), is a member of the highly conserved paired box (PAX)-domain family of transcription factors. PAX5 is essential in normal B-cell lymphopoiesis. It is expressed in pro-B, pre-B and mature B lymphocytes but not in plasma cells. PAX5 is a common target in leukemogenesis of B-ALL ( B-lineage acute lymphoblastic leukemia) along with CDKN2A. Owing to its frequent deletion in B-ALL, PAX5 could be used as one of the molecular markers in diagnosis and monitoring of the disease. This antibody is specific to PAX5. It will not cross react with other PAX members.
|Product Specific Protocols
|WB protocol for BSAP,PAX5 antibody 26709-1-AP
|IHC protocol for BSAP,PAX5 antibody 26709-1-AP
|IP protocol for BSAP,PAX5 antibody 26709-1-AP
|FC protocol for BSAP,PAX5 antibody 26709-1-AP
|Click here to view our Standard Protocols
Cancer Cell Int
Targeting Lymphotoxin Beta and Paired Box 5: a potential therapeutic strategy for soft tissue sarcoma metastasis.
J Cutan Pathol
Superficial sarcomas with CIC rearrangement are aggressive neoplasms: A series of eight cases.
miR-126 downregulates CXCL12 expression in intestinal epithelial cells to suppress the recruitment and function of macrophages and tumorigenesis in a murine model of colitis-associated colorectal cancer